Gelonghui, July 9, 丨 Shu Taishen (300204.SZ) announced that recently, Shu Taishen (Beijing) Biopharmaceutical Co., Ltd. (hereinafter referred to as “Shu Taishen” or the “Company”) received the “Drug Clinical Trial Approval Notice” (Notice No. 2024LP01513, 2024LP01514, 2024LP01515) issued by the State Drug Administration for treating neurotrophic keratitis.
STSP-0902 is a recombinant human nerve growth factor fC fusion protein independently developed by Shu Taishen that targets specific sites. Preclinical experimental data shows that STSP-0902 can activate the TrkA receptor pathway, promote nerve growth, improve corneal integrity and corneal nerve length in rat neurotrophic keratitis models, and increase corneal sensory sensitivity. At the same time, compared with recombinant wild-type human nerve growth factor, STSP-0902 can also reduce the pain response caused by it. STSP-0902 was independently developed by the company, and invention patents have been applied for domestically and internationally.”